FDA Approved: KENGREAL — Supplemental Application (Chiesi USA, Inc.)

View source ↗

Summary

FDA approved a supplemental application for KENGREAL (cangrelor) submitted by Chiesi USA, Inc., authorizing the changes included in the supplemental submission.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Syndrome
• Ischemic Heart Disease

Drugs mentioned

• Kengreal (cangrelor)

Snippet

SUPPL AP for KENGREAL (CANGRELOR)